{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzokeq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzokeq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/42\\\/30\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/42\\\/30\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/42\\\/30\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/42\\\/30\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EHeart failure phenotypes are currently categorized in various ways (eg, as acute vs chronic disease) or by the disease consequences. This article explores the role of some promising new biomarkers as novel approaches to define and treat acute heart failure phenotypes.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EHeart Failure Genomics\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHeart Failure\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiology Genomics\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EAccording to W. Frank Peacock, MD, Baylor College of Medicine, Houston, Texas, USA, a phenotypic division of a condition requires 3 features to be clinically useful:\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\n            \u003Cp id=\u0022p-3\u0022\u003EIt must identify a patient population with unique characteristics.\u003C\/p\u003E\n         \u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\n            \u003Cp id=\u0022p-4\u0022\u003EIts unique characteristics must manifest in a treatment response.\u003C\/p\u003E\n         \u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\n            \u003Cp id=\u0022p-5\u0022\u003EPredicted outcomes in the patient population must be able to be changed by intervention.\u003C\/p\u003E\n         \u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-6\u0022\u003EAlthough heart failure (HF) phenotypes are currently categorized in various ways (eg, as acute vs chronic disease) or by the disease consequences, Dr Peacock stressed that, in his opinion, these methods are unsatisfactory. In a symposium on HF, he joined a panel of speakers who explored the role of some promising new biomarkers as novel approaches to define and treat acute heart failure (AHF) phenotypes.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003ERudolf A. de Boer, MD, University Medical Center, Groningen, The Netherlands, introduced the session with a discussion on galectin-3, an emerging prognostic biomarker in AHF. This bioactive protein is activated in cases of myocardial fibrosis. In the failing heart, it is secreted by macrophages at sites of tissue injury, where it stimulates the release of cytokines that promote fibro-blast differentiation into myofibroblasts [McCullough P et al. \u003Cem\u003ERev Cardiovasc Med.\u003C\/em\u003E 2011], a key step in cardiac remodeling after cardiac injury.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EAccording to Prof de Boer, several studies have demonstrated that an elevated concentration of galectin-3 predicts all-cause mortality in the general population [deBoer RA et al. \u003Cem\u003EJ Intern Med.\u003C\/em\u003E 2012; Ho Je et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012; Hillege HL et al. \u003Cem\u003EJ Intern Med.\u003C\/em\u003E 2001] and new-onset HF [Ginsberg E et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2014 (poster 1114\u2013175); Ho Je et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012]. It has also been shown to correlate with echocardiographic measures of left ventricular (LV) diastolic dysfunction [Seliger SL et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2014 (poster 1114\u2013173)], and to predict outcomes in patients with HF with preserved LV ejection fraction [de Boer RA et al. \u003Cem\u003EAnn Med.\u003C\/em\u003E 2011].\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EGalectin-3 appears to predict short-term outcomes after AHF. In a pooled analysis of 3 AHF studies, elevated galectin-3 was associated with a 2- to 3-fold increased risk of rehospitalization or death within 30 to 120 days of discharge [Meijers WC et al. \u003Cem\u003EAm Heart J.\u003C\/em\u003E 2014]. Its prognostic value with respect to longer-term outcomes still remains less clear, however [Gullestad L et al. \u003Cem\u003EAm Heart J.\u003C\/em\u003E 2012].\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EIn the CORONA trial [Gullestad L et al. \u003Cem\u003EEur Heart J.\u003C\/em\u003E 2012], which examined the effect of galectin-3 on response to statin therapy, data showed that patients with a galactin-3 level \u0026lt; 19 ng\/mL appeared to experience benefit from rosuvastatin therapy, compared with those with higher galactin-3 levels who did not benefit.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EProf de Boer noted that galectin-3 may also be useful in predicting absence of heart disease, and that possibly the most interesting application of galectin-3 may be targeted therapy, because experimental evidence suggests that galectin-3 inhibitors may ultimately be useful for the treatment of HF.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EAccording to Allan S. Jaffe, MD, Mayo Clinic and Medical School, Rochester, Minnesota, USA, ST2 is a biomarker of cardiomyocyte stress that has proven to be a useful predictor of mortality in HF and myocardial infarction (MI). It is a member of the interleukin (IL)-1 receptor family that exists in at least 2 isoforms: a trans-membrane (ST2L) and a soluble circulating form (sST2). Although signaling between IL-33 and ST2L provides an important cardioprotective mechanism, sST2 acts as a decoy receptor of IL33, blocking cardioprotection and leading to myocardial fibrosis.\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EData from one study showed that ST2 levels were significantly elevated in patients with AHF (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001) and also had prognostic value [Januzzi JL et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2007]. High ST2 levels also correlate with an increased risk of 1-year mortality [Rehman SU et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2008].\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EDr Jaffe described ST2 as a \u201cdeath marker\u201d because it is a strong prognosticator for mortality, as further demonstrated by analysis of data from the GREAT network [Lassus J et al. \u003Cem\u003EInt J Cardiol\u003C\/em\u003E. 2013]. He noted that higher levels of ST2 (\u0026gt; 35 ng\/mL) may also identify patients at increased risk of 30-day hospital readmissions. Short-term changes in ST2 throughout time also provide prognostic value, with data showing that, during a 2-week period, increased elevation in sST2 levels increased the risk of mortality, whereas decreased levels reduced the risk of mortality (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001) [Bayes-Genis A et al. \u003Cem\u003ERev Exp Cardiol\u003C\/em\u003E. 2010]. Dr Jaffe also emphasized that unpublished data from his institution have shown that the use of gender-specific cutoff values improves risk stratification, compared with the clinically used single cutoff point of 35 ng\/mL, for secondary end points such as rehospitalization.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EOne interesting observation is that ST2 concentration may be modified by treatments including \u03b2-blockers [Gaggin HK et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2013] and eplerenone [Weir AP et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2010]. The clinical implications of these observations will need to be clarified in future studies. Interesting data have also been reported, suggesting that ST2 and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) combined may be associated with survivors of sudden death [Pascual-Figal DA et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2009]. Dr Jaffe emphasized, however, that there is no clear indication for routine clinical use of ST2 as yet.\u003C\/p\u003E\u003Cp id=\u0022p-16\u0022\u003EDr Peacock noted that assessment of cardiac troponin (cTn) levels should form part of early risk assessment because it provides important prognostic information for patients with AHF. He shared data showing that patients with high troponin levels required more cardiac procedures and longer hospitalization times, and were at high risk of in-hospital death [Peacock WF. \u003Cem\u003EN Engl J Med.\u003C\/em\u003E 2008]\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EIn another study that followed patients from hospital admission to discharge, high concentrations of troponin (\u0026gt; 23.25 ng\/L list assay and 99th percentile) were associated with increased risk of readmission and mortality more than lower levels (\u0026lt; 23.25 ng\/L; HR, 3.547; \u003Cem\u003EP\u003C\/em\u003E = .003) [Xue Y et al. \u003Cem\u003EEur J Heart Fail\u003C\/em\u003E. 2011]. Evaluation of serial troponin levels in these patients also showed that progressively increasing levels in the first 3 measurements after admission comprised a poor prognostic indicator, predicting an increased risk of hospital readmission or death within 90 days, compared with patients whose troponin levels did not continue to increase.\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EDr Peacock added that low levels of troponin may indicate subclinical chronic myocardial injury, and subsequently an increased risk of pathological cardiac remodeling and HF [de Lemos JA, Grundy SM. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012]. An Italian study showed that cTn levels increased in association with LV hypertrophy (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .0001) [Masson S et al. \u003Cem\u003EJ Intern Med.\u003C\/em\u003E 2013]. In another study, patients with this structural abnormality had increased levels of troponin that were reduced by diuretic treatment. Individuals who responded fastest to diuresis were successfully compensated, demonstrating decreased troponin levels (\u003Cem\u003EP\u003C\/em\u003E = .025) that also correlated with decreased levels of NT-proBNP (\u003Cem\u003EP\u003C\/em\u003E = .007) [Ferreira JP et al. \u003Cem\u003ECardiol Res Pract\u003C\/em\u003E. 2014]. Phase 3 data from the RELAX-AHF trial [Metra M et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2013] showed that patients with AHF in early serelaxin treatment experienced a reduction in 180-day mortality compared with those taking placebo [HR, 0.62; 95% CI, 0.43 to 0.88; \u003Cem\u003EP\u003C\/em\u003E = .0076].\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EConsequently, an increase in troponin levels does appear to identify a cohort of patients at elevated risk of death who are more likely to have structural cardiac abnormalities and be less responsive to diuretic therapy. Dr Peacock concluded that clinical studies remain ongoing to determine whether it may also be a phenotypic target for specific intravenous neurohormonal antagonist therapies.\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EDyspnea is one clinically defined phenotype in AHF, and, according to Alan Maisel, MD, Veterans Affairs Medical Center, San Diego, California, USA, pneumonia occurs with HF in up to 15% of patients. He presented data showing that this significantly increases the risk of in-hospital mortality (HR, 1.60; 95% CI, 1.38 to 1.85; \u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001) [Fonarow GC et al. \u003Cem\u003EArch Int Med.\u003C\/em\u003E 2008].\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EHe emphasized the need for rapid evaluation of patients suspected to have pneumonia, to initiate antibiotic therapy, but highlighted the difficulty of diagnosing pneumonia in individuals with preexisting lung disease or AHF. Procalcitonin (PCT) has emerged, however, as one potentially useful protein biomarker with clinical value in the diagnosis of severe bacterial infection and sepsis, evaluation of its severity, and prediction of its course. Its level is low in healthy individuals (\u0026lt; 0.5 ng\/mL), increases markedly in the presence of a bacterial-induced systemic inflammatory response (sepsis is likely with levels \u0026gt; 2 ng\/mL), and decreases with effective treatment of the infection. Dr Maisel discussed studies showing its value in identifying the need for antibiotic therapy for pneumonia, including one demonstrating that PCT levels could be used to tailor antibiotic treatment duration to patients\u0027 individual needs [Christ-Crain M et al. \u003Cem\u003EAm J Resp Crit Care Med.\u003C\/em\u003E 2006].\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EDr Maisel advocated using serial assessment of biomarker levels in patients. He stressed, however, that biomarkers should not be used as stand-alone tests, but should be appropriately selected and combined to form panels to improve disease diagnosis. He also noted that PCT evaluation improves physicians\u0027 decision making about the presence of pneumonia in patients with HF (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E) [Maisel A et al. \u003Cem\u003EEur J Heart Fail\u003C\/em\u003E. 2012].\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/42\/30\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Relationship Between Procalcitonin Assessment and Physician Decision Making\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1536440991\u0022 data-figure-caption=\u0022Relationship Between Procalcitonin Assessment and Physician Decision Making\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/42\/30\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/42\/30\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/42\/30\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/15366\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \n            \u003Cp id=\u0022p-23\u0022 class=\u0022first-child\u0022\u003ERelationship Between Procalcitonin Assessment and Physician Decision Making\u003C\/p\u003E\n         \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-1\u0022\u003EPCT, procalcitonin.\u003C\/q\u003E\u003Cq class=\u0022attrib\u0022 id=\u0022attrib-2\u0022\u003EAdapted from Maisel A et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. \u003Cem\u003EEur J Heart Fail\u003C\/em\u003E. 2012;14:278\u2013286. With permission from European Society of Cardiology.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-24\u0022\u003EAccording to Martin M\u00f6ckel, MD, Charit\u00e9 University, Berlin, Germany, in the heart, adrenomedullin (ADM) is secreted predominantly by vascular cells. This protein provides an endocrine signal that is involved in pathway cross-talk among endothelial, smooth muscle, and cardiac muscle cells, resulting in vasodilatory, diuretic, and cardioprotective effects.\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EProf M\u00f6ckel noted that, due to its inherent instability, ADM is measured in plasma as the more stable prohormone, mid-region pro-adrenomedullin (MRpro-ADM). He added that MRpro-ADM levels are significantly elevated in patients with AHF and dyspnea, and strongly predict mortality, thereby defining a phenotype of patients at high risk of death. Prof M\u00f6ckel also highlighted the value of combining biomarkers in certain scenarios, sharing data demonstrating increased diagnostic and prognostic value when MRpro-ADM and atrial natriuretic peptide are combined [Shah RV et al. \u003Cem\u003EEur Heart J.\u003C\/em\u003E 2010].\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003EAlthough data from the BACH trial demonstrated value in the use of MRpro-ADM to guide disposition of patients with acute dyspnea [Moeckel M et al. \u003Cem\u003EEmerg Med J.\u003C\/em\u003E 2013], Prof M\u00f6ckel concluded that the therapeutic value of this biomarker also remains undetermined.\u003C\/p\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/42\/30.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzokeq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzokeq\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}